BiotechTube

Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome

Trial Timeline

Feb 1, 1989 → Dec 1, 2007

NCT ID
NCT00191113

About Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate

Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate is a phase 3 stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00191113. Target conditions include Turner Syndrome.

What happened to similar drugs?

3 of 7 similar drugs in Turner Syndrome were approved

Approved (3) Terminated (0) Active (4)
✅HumatropeEli LillyApproved
✅r-hGHMerckApproved
✅estradiolNovo NordiskApproved
🔄SomatropinEli LillyPhase 3
🔄17 beta estradiolEli LillyPhase 3
🔄Somapacitan + Norditropin®Novo NordiskPhase 3
🔄Somatropin (rDNA origin)IpsenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00191113Phase 3Completed

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
HumatropeEli LillyApproved
43
17 beta estradiolEli LillyPhase 3
40
r-hGHMerckApproved
43
Somapacitan + Norditropin®Novo NordiskPhase 3
44
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
36
Somatropin (rDNA origin)IpsenPhase 3
37